Floatz logo

Gemogenovatucel-T

Rare

Gradalis, Inc.Cell therapyPhase 3Dormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Rare cohort.

Asset / SponsorPhaseRating
Burosumab
Bicetre Hospital
Phase 4BB
Irinotecan
Gradalis, Inc.
Phase 3B
Crofelemer
Napo Pharmaceuticals, Inc.
Phase 2/3B
Nivestim
Hospices Civils de Lyon
Phase 2/3B
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer
Prisma Health-Upstate
Phase 2CCC

View all 11 →

Same molecule, other indications

Gemogenovatucel-T is also rated in:

uterine cancerDormant
B
Indicative · Phase 2
57 / 100
View asset →
Ewing sarcomaDormant
B
Indicative · Phase 3
57 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative · Phase 2
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →